Vesync Co (OTC:VSYNF) Stock, Quote.Headers.trade-ideas

Vesync focuses on online marketing and sale of self-designed and self-developed small home appliances and smart home devices to North American, European and Asian markets. In 2023, more than 75% of sales were generated through Amazon, and the remainder came from other e-commerce platforms and offline retailers. The company owns three core brands: Levoit for home environment appliances, Etekcity for smart home gadgets, health monitoring devices, outdoor recreation products, and personal-care products, and Cosori for kitchen and dining appliances.

Vesync Co Ltd

JMP Securities analyst David Scharf maintains Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) with a Market Outperform and raises the price target from $93 to $103.

News

Price Target

Analyst Ratings

ENVA

JMP Securities Maintains Market Outperform on Enova International, Raises Price Target to $103

Electric vehicle maker Tesla, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are poised for outperformance on Monday, as they are solidly higher <a href="https://www.benzinga.com/premarket">in premarket trading.</a>
The stock fell 8.78% or $20.97 last Friday before closing at $217.80, the lowest close since Sept.9. 
The premarket strength could point to bargain hunting after the stock&#8217;s 13% plunge in the week ended Oct. 13. Even if the stock stages a recovery in the near term, a sustainable uptrend is unlikely until the company&#8217;s third-quarter earnings report is out. Investors are skittish about the margin impact of the incentives it had in place to stimulate sales. 
See Also: <a href="https://www.benzinga.com/money/how-to-buy-tesla-stock">How To Buy Tesla (TSLA) Stock</a>
Tesla is scheduled to announce its quarterly results after the market closes on Oct. 23. Analysts, on average, expect the company to report earnings per share of 57 cents, down from 66 cents a year ago. Revenue may have increased 14.70% to $25.34 billion. The company reported its first year-over-year delivery growth in three quarters earlier this month.
As Tesla slumped nearly 9% on Friday, Cathie Wood-run Ark Invest&#8217;s ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) bought 12,730 shares in the Elon Musk-led company. At Friday&#8217;s closing price, the purchase is worth $2.77 million.
The stock could also be getting a shot in the arm from sister company <a href="https://www.benzinga.com/news/24/10/41305295/spacex-notches-another-milestone-with-first-booster-catch">SpaceX&#8217;s success in catching the Starship rocket</a> booster for the first time as it returned to the Earth following its launch.
In premarket, Tesla stock rose 1.13% to $220.26, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41303249/tesla-stock-dives-after-we-robot-event-lucids-q3-deliveries-beat-gm-reworks-battery-strategy-and">Tesla Stock Dives After &#8216;We, Robot&#8217; Event, Lucid&#8217;s Q3 Deliveries Beat, GM Reworks Battery Strategy And More: Biggest EV Stories Of The Week</a></li>
</ul>
Image via Flickr

Equities

Markets

Movers

Trading Ideas

ARKW

TSLA

Tesla Stock Climbs Higher In Monday Premarket: What's Fueling The Surge?

On Friday, the FDA approved Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)&nbsp;Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency), or hemophilia B (congenital factor IX deficiency).
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via a pre-filled, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41296235/u-s-fda-approves-pfizers-hympavzi-marstacimab-hncq-for-the-treatment-of-adults-and-adolescents-wit" rel="noreferrer noopener">auto-injector pen</a>.
Hympavzi can offer a subcutaneous treatment option with a once-weekly dosing schedule and minimal preparation required for each individual administration.
Hemophilia is a family of rare genetic blood diseases caused by a clotting factor deficiency (FVIII in hemophilia A, FIX in hemophilia B), impacting more than 800,000 people globally.
Results from the Phase 3 BASIS trial (<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03938792&amp;esheet=54134066&amp;newsitemid=20241009505480&amp;lan=en-US&amp;anchor=NCT03938792&amp;index=1&amp;md5=2f50558fdab1e48356374ad447cabc38" rel="noreferrer noopener">NCT03938792</a>) supported the FDA approval of Hympavzi.
In the study, Hympavzi reduced the annualized bleeding rate (ABR) for treated bleeds by 35% and 92% after a 12-month active treatment period compared to routine prophylaxis (RP) and on-demand (OD) treatment, respectively, in patients with hemophilia A or B without inhibitors.
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion&nbsp;for marstacimab for the routine prophylaxis of bleeding episodes in adults and adolescents with severe hemophilia A or hemophilia B.
Reuters, citing some analysts, highlights that Hympavzi sales are expected to reach $300 million by 2030.
Earlier this year, FDA approved&nbsp;Pfizer&#8217;s Beqvez (fidanacogene&nbsp;elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated,&nbsp;serious spontaneous&nbsp;bleeding episodes, and do not have neutralizing antibodies to&nbsp;adeno-associated&nbsp;virus&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38468053/fda-green-lights-pfizers-gene-therapy-for-rare-bleeding-disorder-hemophilia" rel="noreferrer noopener">serotype Rh74var capsid</a>.&nbsp;
Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves rather than the current standard of care, which requires regular intravenous infusions of FIX that&nbsp;are often administered&nbsp;multiple times a week or&nbsp;multiple&nbsp;times a month.
In July, Pfizer, in collaboration with Sangamo Therapeutics Inc, released results from the Phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for adult patients with moderately&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39937203/sangamo-stock-spikes-as-pfizer-partnership-meets-goal-in-late-stage-study" rel="noreferrer noopener">severe to severe hemophilia A</a>.
Price Action: PFE stock is down 0.14% at $29.12 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41297538/amazons-ai-driven-aws-growth-to-power-outperformance-analysts" target="_blank" rel="noreferrer noopener">Amazon&#8217;s AI-Driven AWS Growth To Power Outperformance: Analysts</a>.</li>
</ul>

Biotech

Large Cap

Health Care

Media

General

SGMO

FDA Approves Pfizer's Second Hemophilia Drug With Six Months

Baird analyst David Koning maintains Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Neutral and raises the price target from $28 to $30.

TOST

Baird Maintains Neutral on Toast, Raises Price Target to $30

Contracts

BWMN

Bowman Secures $1.2M Contract For Asset Management And Compliance Tracking In Delaware Basin

ProKidney Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five posters, including one late-breaking clinical trial, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA. &nbsp;
The titles for the accepted abstracts are provided below and accessible online at: <a href="https://www.globenewswire.com/Tracker?data=_DoGGOj70O04OyMRh-pGNyESSJeuKN72uESZ_ZgrmiGIKyfb-JylbedxJHt_bMJpkpmDXKHeYKZRUsplCNHsZydrW08zK7ss2yGoroEFCFmksFxO5Oaqs31XiZjmoNDHfp269Lh87DugMrbywVi8I3vZ_-wLphp-AsVT1Nm2-rU1I0pxUSP4MH30llAgGXuZoBEcrapaSCxrPvhEwhPEkRBhe6mES12SUTWgurP9-Nvjp-A2h_mE4IfDglS1U8LD">https://www.asn-online.org/education/kidneyweek/2024/program-search-abstract.aspx</a>
Late-Breaking Poster Presentation
Rilparencel Autologous Cell Therapy in Patients with Diabetes and Advanced CKD: Phase 2 Interim Results Session Title: Late-Breaking Clinical Trials Posters Session Date &amp; Time: October 24, 2024, from 10:00 AM to 12:00 PM PDT Poster Board #: TH-PO1177
Poster Presentations
Phase 3 Clinical Trial Candidate Rilparencel Demonstrates Consistent Phenotypic Characteristics During Ex Vivo Culture Expansion Process Session Title: Development, Organoids, Injury, and Regeneration Session Date, Time: October 24, 2024, from 10:00 AM to 12:00 PM PDT Poster Board #: TH-PO415
Phase 3 Clinical Candidate Rilparencel Demonstrates Weak Association with Renal Epithelial Senescence-Associated Secretory Phenotype Session Title: CKD: Kidney Function and Extrarenal Complications Session Date, Time: October 25, 2024, from 10:00 AM to 12:00 PM PDT Poster Board #: FR-PO1156
Late Clinical-stage Candidate Rilparencel's Effect on Kidney Function and Biological Pathways in a Type 2 Diabetes and CKD Patient Subset Session Title: Diabetic Kidney Disease: Basic - 2 Session Date, Time: October 26, 2024, from 10:00 AM to 12:00 PM PDT Poster Board #: SA-PO263
Phase 3 Clinical Candidate Rilparencel Demonstrates Distinct Secretomic Signatures at Key Points in Manufacturing, Suggesting a Reduced Inflammatory and Fibrotic Profile Session Title: Diabetic Kidney Disease: Basic - 2 Session Date, Time: October 26, 2024, from 10:00 AM to 12:00 PM PDT Poster Board #: SA-PO287

PROK

ProKidney to Present Cell Therapy Data for CKD at ASN Kidney Week 2024

Baird analyst David Koning maintains Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) with a Outperform and raises the price target from $24 to $25.

Baird Maintains Outperform on Paymentus Holdings, Raises Price Target to $25

Snoop Dogg, widely regarded as one of the greatest rappers of all time, has been known for his cryptocurrency ventures and has not shied away from endorsing the asset class on public forums.
What happened: Right from his foray into the <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38202011/jay-z-eminem-and-snoop-doggs-crypto-portfolios-revealed-who-owns-the-most">non-fungible token (NFT) space</a> to making social media posts on <a href="https://in.benzinga.com/content/33146419/if-you-invested-1-000-in-dogecoin-when-snoop-dogg-first-tweeted-about-it-heres-how-much-youd-have-ri">popular coins</a> like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), the rap legend has attracted attention from cryptocurrency enthusiasts.
The "Doggfather" has also frequently mentioned the world's most valuable cryptocurrency, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), in his social posts.
Back in 2013, he posted on Twitter, now X, that he&#8217;d accept Bitcoin as payment for his upcoming album.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">My next record available in bitcoin n delivered in a drone.
&mdash; Snoop Dogg (@SnoopDogg) <a href="https://twitter.com/SnoopDogg/status/407350025677586433?ref_src=twsrc%5Etfw">December 2, 2013</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The post created a firestorm, with popular cryptocurrency payment provider BitPay and trading platform Coinbase seizing on the opportunity and offering to set this up for the rap star.
As it turned out, nothing came out of the post, and it was most likely a PR stunt for his next album, &#8220;Bush,&#8221; which was released in May 2015.
However, suppose you parked $1000 in Bitcoin when it traded at $1,043.33 a unit on the day the tweet was made, it would have fetched you 0.95846 units of the digital currency.
As of this writing, one Bitcoin was exchanging hands at $64,093.01, making your portfolio worth $61,431.196. This reflected a whopping 6043.11% return.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41306653/anthony-scaramucci-praises-trump-for-shifting-the-crypto-debate-hes-now-forced-the-democra">Anthony Scaramucci Praises Trump For Shifting The Crypto Debate: &#8216;He&#8217;s Now Forced The Democrats To Come Back Into The Middle&#8217;</a>
Why It Matters: While we don&#8217;t know if Snoop Dogg regrets not putting his money where his mouth was, the hip-hop musician would have profited handsomely if he had pursued the idea.&nbsp;&nbsp;
Months after the aforementioned tweet, Grammy Award-winning rapper 50 Cent became the <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39131172/rapper-50-cent-accepted-bitcoin-for-his-album-animal-ambition-10-years-ago-heres-how-much-">first artist to accept Bitcoin as payment</a> for his album &#8220;Animal Ambition,&#8221; collecting as many as 700 BTCs through the sale.
Price Action: At the time of writing, Bitcoin was exchanging hands at $64,093.01, up 1.91% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.  
Image Via Shutterstock
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41299293/michael-saylor-reveals-microstrategys-endgame-is-to-be-the-leading-bitcoin-bank-with-100b-">Michael Saylor Reveals MicroStrategy&#8217;s Endgame Is To Be The &#8216;Leading Bitcoin Bank&#8217; With $100B-$150B In BTC Holdings</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Entertainment

$BTC

$DOGE

If You Invested $1000 In Bitcoin When Snoop Dogg Tweeted His Next Record Is Available In King Crypto, Here's How Much It'd Be Worth Today

Living in a Florida condo might sound like a dream, but for many retirees, that dream becomes a nightmare. <a href="https://www.benzinga.com/real-estate/24/09/40761208/florida-homeowners-association-board-resigns-en-masse-over-60-000-special-assessment-dispute-find-ou">Homeowner&#8217;s association (HOA</a>) fees across the state are skyrocketing and people with fixed incomes feel pressure to relocate.
A recent Redfin analysis found that HOA fees in several Florida metro areas have increased dramatically, surpassing the rate of hikes in other U.S. cities. This has left condo owners with tough choices: sell at a loss or stay in a home where monthly costs keep climbing.Don't Miss:
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
<li>Beating the market through ethical real estate investing' — t<a href="https://www.benzinga.com/money/invest-with-roots">his platform aims to give tenants equity in the homes they live in while scoring 17.17% average annual returns for investors – here&#8217;s how to join with just $100</a></li>
</ul>
"Many buildings – even those without amenities – now have HOA dues north of $1,000 a month," said Rafael Corrales, a Redfin Premier agent in Miami. "Special assessments are being tacked on and a lot of condo owners, especially retirees, are being forced to sell because they just can't keep up."
See Also: A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a>
According to Redfin's data, HOA fees rose 6% on average nationwide during the three months ending July 31. But Florida's numbers are much higher. Tampa saw the biggest spike, with dues up 17.2% year over year. Orlando followed close behind, with fees climbing 16.7%. Fort Lauderdale wasn't far off either, experiencing a 16.2% increase.
Other Florida cities, like West Palm Beach and Jacksonville, also saw significant rises, with 12.8% and 7.6% respectively. On the surface, Miami seems to have escaped this trend with a smaller jump of 5.7%. However, that's because Miami's dues were already among the highest in the country, averaging $835 a month.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
One of the main reasons why the costs are rising fast is the passage of Senate Bill 4-D, introduced after the tragic collapse of the Surfside Condo in 2021, which killed over 100 people. The new law requires stricter inspections and mandates higher reserve funds for repairs. To comply, HOAs are raising dues significantly.
Insurance is another major factor. As cited by Redfin survey, three-quarters of Florida homeowners reported sharp increases in property insurance premiums. These, combined with rising inflation, have increased the cost of living for condo owners across the state.
Trending: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
As HOA fees climb, property values are taking a hit. Condo sale prices in Jacksonville fell 6.6% year-over-year, the sharpest drop of any metro area. Tampa wasn't far behind, with a 4.9% decline, while Fort Lauderdale saw prices fall by 4.2%. Even Miami and Orlando, usually more resilient markets, saw declines of 2.2% and 0.5%, respectively.
<a href="https://www.benzinga.com/real-estate/24/06/39293984/grant-cardone-says-owning-rental-properties-will-pay-big-dividends-as-u-s-rents-hit-highest-levels-s">Property owners</a> now face a tough dilemma: either hold on as rising dues become unaffordable or sell their condo at a reduced value. Mortgage rates remain high and other Florida condos are hit with similar fee hikes, making affordable housing even harder to find.
Read Next:
<ul>
<li>Can you guess which type of investments Morgan Stanley says will reach $2.7 trillion by 2027?<a href="https://www.benzinga.com/money/percent"> It even offers up to 20% APY potential to accredited investors up to $300 back in bonus for new users.</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Personal Finance

Exorbitant HOA Fees Are Driving Florida Retirees To Relocate – Here's Why Costs Are Spiraling So High In The Sunshine State

Baird analyst David Manthey maintains Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) with a Neutral and raises the price target from $67 to $80.

FAST

Baird Maintains Neutral on Fastenal, Raises Price Target to $80

Baird analyst David George downgrades KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) from Outperform to Neutral and lowers the price target from $18 to $17.

Downgrades

Baird Downgrades KeyCorp to Neutral, Lowers Price Target to $17

Macro Economic Events

Econ #s

Economics

Reported Earlier, China New Loans For September 1,590.0B Vs. 1,090.0B Est.; 900.0B Prior

Reported Earlier, China Trade Balance (USD) For September 81.71B Vs. 89.80B Est.; 91.02B Prior

Reported Earlier, China Imports (YoY) For September 0.3% Vs. 0.9% Est.; 0.5% Prior

JMP Securities analyst David Scharf maintains Atlanticus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLC#NASDAQ">ATLC</a>) with a Market Outperform and raises the price target from $39 to $45.

ATLC

JMP Securities Maintains Market Outperform on Atlanticus Holdings, Raises Price Target to $45

Reported Earlier, China Exports (YoY) For September 2.4% Vs. 6.0% Est.; 8.7% Prior

-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 --

QTTB

Q32 Bio To Reveal Phase 1 Clinical Trial Results For Tissue-Targeted Complement Inhibitor ADX-097 At The American Society Of Nephrology Kidney Week 2024

Three U.S.-based economists have been awarded the prestigious Nobel Prize in Economic Sciences for their significant contributions to understanding global wealth inequality. 
As per the official press release, U.S.-based economists Daron Acemoglu, Simon Johnson, and James Robinson were awarded the Nobel Prize in Economic Sciences on Monday. The trio was recognized for their groundbreaking research on wealth inequality between nations.
The Nobel Committee highlighted their work on how societies with inadequate legal frameworks and exploitative institutions fail to achieve economic growth. Acemoglu and Johnson are professors at the Massachusetts Institute of Technology, while Robinson is the director of the University of Chicago&#8217;s Pearson Institute.
See Also: <a href="https://www.benzinga.com/news/24/10/41303300/mary-trump-because-donald-is-a-world-class-hypocrite-it-turns-out-his-interviews-have-been-edited?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mary Trump: &#8216;Because Donald Is A World-Class Hypocrite, It Turns Out His Interviews Have Been Edited&#8217;</a>
Their influential 2012 book, &#8220;Why Nations Fail: The Origins of Power, Prosperity, and Poverty,&#8221; delves into the roots of inequality and the factors that enable some countries to thrive. Jakob Svensson from Stockholm University praised their empirical and theoretical contributions to understanding global inequality.
The winners will share the prize money of 11 million Swedish kronor ($1.058 million), awarded by the Swedish central bank. This award, formally known as the &#8220;Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel,&#8221; was first introduced in 1968.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41303750/elon-musks-new-cybercab-does-not-have-stainless-steel-exterior-panels-like-cybertruck-despite-other?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s New Cybercab Does Not Have Stainless Steel Exterior Panels Like Cybertruck Despite Other Rese</a></li>
</ul>
Image via Wikimedia Commons
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

US Economists Daron Acemoglu, Simon Johnson And James Robinson Win Nobel Prize For Groundbreaking Research On Global Wealth Inequality

Guggenheim analyst Seamus Fernandez initiates coverage on Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) with a Buy rating and announces Price Target of $16.

Initiation

TENX

Guggenheim Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $16

Morgan Stanley analyst Angel Castillo downgrades Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Equal-Weight to Underweight and lowers the price target from $349 to $332.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Vesync Co

Vesync Co (VSYNF) Forecast

Vesync Co (OTC:VSYNF) Stock, Quote.Headers.trade-ideas